187 related articles for article (PubMed ID: 8836386)
41. Evolving Approaches in Research and Care for Ovarian Cancers: A Report From the National Academies of Sciences, Engineering, and Medicine.
Levine DA; Karlan BY; Strauss JF
JAMA; 2016 May; 315(18):1943-4. PubMed ID: 26934631
[No Abstract] [Full Text] [Related]
42. Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up.
Tuxen MK; Sölétormos G; Dombernowsky P
Scand J Clin Lab Invest; 2002; 62(3):177-88. PubMed ID: 12088336
[TBL] [Abstract][Full Text] [Related]
43. Level and evaluation of tumor marker CA-125 in ovarian cancer patients in Khyber Pakhtunkhwa, Pakistan.
Ahmad B; Nawaz S; Ali S; Bashir S; Mahmood N; Gul B
Asian Pac J Cancer Prev; 2015; 16(1):185-9. PubMed ID: 25640349
[TBL] [Abstract][Full Text] [Related]
44. Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer.
Zhang YJ; Cao LY; Fu ZZ; Wang YJ; Wang GX; Gu T
J Cancer Res Ther; 2015; 11(2):375-80. PubMed ID: 26148603
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecologic diseases.
Guadagni F; Marth C; Zeimet AG; Ferroni P; Spila A; Abbolito R; Roselli M; Greiner JW; Schlom J
Am J Obstet Gynecol; 1994 Nov; 171(5):1183-91. PubMed ID: 7977516
[TBL] [Abstract][Full Text] [Related]
46. Is CA 125 actually a tumor marker for ovarian cancer?
Collazos J
Acta Oncol; 1995; 34(2):268. PubMed ID: 7718270
[No Abstract] [Full Text] [Related]
47. Monitoring ovarian cancer: CA125 trial stirs controversy.
Chitale R
J Natl Cancer Inst; 2009 Sep; 101(18):1233-5. PubMed ID: 19738165
[No Abstract] [Full Text] [Related]
48. Cancer: Missing the mark.
Buchen L
Nature; 2011 Mar; 471(7339):428-32. PubMed ID: 21430749
[No Abstract] [Full Text] [Related]
49. [Level of CA125 and hemoglobin as prognostic factors ovarian cancer].
Chovanec J; Bienertová-Vasků J; Dostálová Z; Minár L
Ceska Gynekol; 2009 Aug; 74(4):269-73. PubMed ID: 20564980
[TBL] [Abstract][Full Text] [Related]
50. [Expression of CA-125 in ovarian cancer].
Mircea R; Frîncu DL; Dumitrache F
Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):1191-4. PubMed ID: 20191897
[TBL] [Abstract][Full Text] [Related]
51. The myth of measurable disease in ovarian cancer: revisited.
Markman M
Cancer Invest; 2009 Jan; 27(1):11-2. PubMed ID: 19160094
[TBL] [Abstract][Full Text] [Related]
52. Clinical practice. Screening for ovarian cancer.
Clarke-Pearson DL
N Engl J Med; 2009 Jul; 361(2):170-7. PubMed ID: 19587342
[No Abstract] [Full Text] [Related]
53. Advances in the early detection of ovarian carcinoma.
Garner EI
J Reprod Med; 2005 Jun; 50(6):447-53. PubMed ID: 16050569
[TBL] [Abstract][Full Text] [Related]
54. The Dangers of Using Tumor Markers to Evaluate Nonspecific Symptoms: A Teachable Moment.
Mortaji P; Lebduska E
JAMA Intern Med; 2020 Jul; 180(7):1004. PubMed ID: 32391883
[No Abstract] [Full Text] [Related]
55. [The accuracy of CT and tumor markers in the detection of a recurrent ovarian carcinoma].
Wakabayashi Y; Ishida J; Kotake F; Hirose M; Kawana K; Abe K; Amino S; Negishi Y; Akiya K
Gan No Rinsho; 1989 Sep; 35(10):1127-31. PubMed ID: 2550684
[TBL] [Abstract][Full Text] [Related]
56. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass.
Hogdall EV; Høgdall CK; Tingulstad S; Hagen B; Nustad K; Xu FJ; Bast RC; Jacobs IJ
Int J Cancer; 2000 Nov; 89(6):519-23. PubMed ID: 11102897
[TBL] [Abstract][Full Text] [Related]
57. Letter commenting on the article "CA 125 expression pattern, prognosis and correlation with serum CA 125 in ovarian tumor patients" (104:508-515) by Hogdall, et al and on the Editorial "CA 125: megadaltons of novel opportunities" (104:505-507).
van Altena AM; de Hullu JA; Massuger LF
Gynecol Oncol; 2007 Nov; 107(2):355-6. PubMed ID: 17707896
[No Abstract] [Full Text] [Related]
58. Biomarker discovery in ovarian cancer.
Tung CS; Wong KK; Mok SC
Womens Health (Lond); 2008 Jan; 4():27-40. PubMed ID: 19072449
[TBL] [Abstract][Full Text] [Related]
59. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
[TBL] [Abstract][Full Text] [Related]
60. HE4 and its evolving role in assessing tumor prognosis in gynecological and systemic malignancies.
Kapoor S
Arch Gynecol Obstet; 2013 Sep; 288(3):713. PubMed ID: 23494198
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
